Hasni, Dita
Unknown Affiliation

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

GAMBARAN SINDROM EKSTRAPIRAMIDAL PADA PASIEN SKIZOFRENIA YANG MENDAPAT TERAPI ANTIPSIKOTIK Hasni, Dita; Ridho, Muhammad; Anissa, Mutiara
Jurnal Kedokteran YARSI Vol 27, No 3 (2019): SEPTEMBER - DESEMBER 2019
Publisher : Lembaga Penelitian Universitas YARSI

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33476/jky.v27i3.983

Abstract

Prevalensi skizofrenia di Sumatra Barat adalah 1.9 per seribu penduduk. Terapi utama skizofrenia menggunakan antipsikotik. Penggunaan antipsikotik dapat menyebabkan efek samping sindrom ekstrapiramidal (EPS) pada pasien skizofrenia, yang dapat meningkatkan morbiditas, menurunkan kepatuhan minum obat, dan menurunkan kualitas hidup. Penelitian ini bertujuan untuk melihat gambaran kejadian efek samping sindrom ekstrapiramidal yang terjadi pada pasien skizofrenia yang mendapatkan terapi antipsikotik. Diikut sertakan 89 pasien pada penelitian cross sectional ini. Pengambilan data dilakukan secara consecutive sampling di poli rawat jalan RSJ HB Saanin Padang setelah memenuhi kriteria inklusi dan ekslusi. Penelitian ini menggunakan kuisioner Simpson Angus Extrapyramidal Side Effect Scale sebagai penentuan kriteria EPS. Pada penelitian ini diperoleh data pasien skizofrenia yang mengalami efek samping EPS sebesar 41,6 %, dengan antipsikotik tipikal sebesar 60%, antipsikotik atipikal sebesar 35.8 %, dan antipsikotik kombinasi sebesar 48.4% dari total responden. Pada penelitian ini diperoleh EPS yang banyak diderita adalah parkinsonisme
Profile of Leptin Levels in Schizophrenic patients Receiving Antipsychotic Therapy in Prof. Dr. HB Saanin Hospital Padang Hasni, Dita; Sagala, Indah Cahya Aminta; Anissa, Mutiara; Eldrian, Febianne
Jurnal Kedokteran Brawijaya Vol 31, No 2 (2020)
Publisher : Fakultas Kedokteran Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.jkb.2020.031.02.7

Abstract

Weight-gain is one of the antipsychotic side effects, and it can increase the risk factor of metabolic syndrome. Several studies relate it to increase leptin levels. This research was conducted to determine the profile of leptin levels in schizophrenic patients who were receiving antipsychotic therapy at Prof. DR. HB Saanin Mental Hospital. The research was conducted from November 2019 to January 2020 on schizophrenic patients who were taking antipsychotic drugs. This research was conducted on 50 samples by using consecutive sampling techniques. Data analysis using univariate are presented in geometric mean and CI 95%. Moreover, a Comparison of leptin levels between groups was performed by T-test and one-way ANOVA. The average leptin level from 50 samples of schizophrenic patients was 5.12µg/ml (CI 95%=3.32-7.90). The highest average leptin level is from the 46-55 year age group which is 11.32µg/ml (CI 95% =5.24 - 24.42), female is  13.29µg/ml (CI 95%=5.84-30.26), BMI ≥30kg/m2  is 12.84µg/ml (CI 95%=4.31-38.23), subjects with above-average waist circumference is 5.54µg/ml ( CI 95%=3.45-8.90), and the atypical group of drugs is 6.08µg/ml (IK 95%=3.41-10.84). Increasing levels of leptin occur in schizophrenic patients who were 46-55 y.o, female BMI ≥30kg/m2, above-average waist circumference, and receiving atypical antipsychotics.